



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2025**

					Rs. in Million
Sl. No.	Particulars	3 Months ended June 30, 2025	Preceding 3 Months ended March 31, 2025	Corresponding 3 Months ended in the previous year June 30, 2024 (Restated)	Previous year ended March 31, 2025
		UNAUDITED	AUDITED (Refer note 6)	UNAUDITED (Refer note 4 & 5)	AUDITED
		(1)	(2)	(3)	(4)
	Continuing Operations				
	Income				
I	Revenue from operations	4,986.16	5,559.58	5,130.00	21,394.23
II	Other income	17.58	121.22	80.91	461.88
III	Total income (I + II)	5,003.74	5,680.80	5,210.91	21,856.11
	IV Expenses				
	(a) Cost of materials consumed	2,109.77	2,682.89	2,264.37	10,481.06
	(b) Purchases of stock-in-trade	157.48	106.53	122.14	626.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	154.61	33.00	146.71	(272.03)
	(d) Employee benefits expense	940.40	918.63	988.02	3,775.91
	(e) Finance costs	304.48	293.60	405.13	1,459.12
	(f) Depreciation and amortisation expense	221.38	223.71	206.22	846.08
	(g) Other expenses	951.59	1,139.21	958.28	4,158.56
	Total expenses (IV)	4,839.71	5,397.57	5,090.87	21,075.01
V	Profit before exceptional items and tax (III - IV)	164.03	283.23	120.04	781.10
VI	Exceptional item	-	-	-	(0.27)
VII	Profit before tax (V + VI)	164.03	283.23	120.04	780.83
VIII	Tax expense/ (benefit)				
	- Current tax	(0.47)	(52.36)	10.59	(14.64)
	- Deferred tax	31.03	174.31	1.11	203.91
	Total tax expense (VIII)	30.56	121.95	11.70	189.27
IX	Profit after tax from continuing operations for the period (VII - VIII)	133.47	161.28	108.34	591.56
X	Discontinued operations (Refer note 5)				
	- Gain on disposal of assets / settlement of liabilities attributable to the discontinued operations (net)	-	-	28,270.55	28,270.55
XI	Profit before tax from discontinued operations	-	-	28,270.55	28,270.55
	- Tax expense / (benefit) of discontinued operations	-	-	-	-
XII	Profit after tax from discontinued operations	-	-	28,270.55	28,270.55
XIII	Profit for the period (IX + XII)	133.47	161.28	28,378.89	28,862.11



STRIDES PHARMA SCIENCE LIMITED
CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.
 Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2025

					Rs. in Million
Sl. No.	Particulars	3 Months ended June 30, 2025	Preceding 3 Months ended March 31, 2025	Corresponding 3 Months ended in the previous year June 30, 2024 (Restated)	Previous year ended March 31, 2025
		UNAUDITED	AUDITED (Refer note 6)	UNAUDITED (Refer note 4 & 5)	AUDITED
		(1)	(2)	(3)	(4)
XIV	Other comprehensive income				
A	(i) Items that will not be reclassified to statement of profit and loss	-	(71.90)	-	(71.90)
	(ii) Income tax relating to items that will not be reclassified to statement of profit and loss	-	25.12	-	25.12
B	(i) Items that may be reclassified to statement of profit and loss	(93.57)	37.92	26.70	23.54
	(ii) Income tax relating to items that may be reclassified to statement of profit and loss	32.70	(13.26)	(9.33)	(8.23)
	Total other comprehensive (loss)/ income, net of tax for the period (XIV)	(60.87)	(22.12)	17.37	(31.47)
XV	Total comprehensive income for the period (XIII + XIV)	72.60	139.16	28,396.26	28,830.64
	Earnings per equity share (face value of Rs. 10/- each) (for continuing operations)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	(a) Basic (Rs.)	1.45	1.75	1.18	6.43
	(b) Diluted (Rs.)	1.45	1.75	1.18	6.43
	Earnings per equity share (face value of Rs. 10/- each) (for discontinued operations)				
	(a) Basic (Rs.)	-	-	307.59	307.25
	(b) Diluted (Rs.)	-	-	307.01	307.22
	Earnings per equity share (face value of Rs. 10/- each) (for total operations)				
	(a) Basic (Rs.)	1.45	1.75	308.77	313.68
	(b) Diluted (Rs.)	1.45	1.75	308.19	313.65
	See accompanying notes to the Standalone Results				



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.

Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

STATEMENT OF STANDALONE UNAUDITED RESULTS

FOR THE QUARTER ENDED JUNE 30, 2025

Notes:

- 1 These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 29, 2025. The statutory auditor has carried out a limited review of the above results for the quarter ended June 30, 2025 and have issued an unmodified opinion.
- 3 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Company's performance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently applied to record revenue and expenditure in individual segments.

Pursuant to the Scheme of demerger explained in Note 5, the CODM has started evaluating the business, including resource allocation and performance assessment as a single segment, i.e. "Pharmaceutical". Consequently, the Company has only one reportable segment and accordingly no disclosures are made as required under Ind AS 108, in current and comparative periods.

Pharmaceutical segment represents the business of development, manufacture and commercialization of pharmaceutical products other than biological drugs.

- 4 On August 2, 2023, the Board of Directors of Strides approved the Scheme of Amalgamation ('the Scheme') u/s 230 to 232 of the Companies Act, 2013, between Strides Pharma Science Limited ('the transferee Company') and Strides Alathur Private Limited (formerly known as Vivimed Lifesciences Private Limited) ('the transferor Company') with an appointed date of April 1, 2023. The Scheme has been approved by the National Company Law Tribunal ('NCLT') Mumbai bench, vide their order dated August 13, 2024 and a certified copy has been filed by the Company with the Registrar of Companies, Mumbai, Maharashtra, on September 12, 2024.

The appointed date as per the NCLT approved Scheme is April 1, 2023, which is the same as the beginning of the preceding year in the standalone financial results and hence, in line with the Scheme, the combination has been accounted for from that date as per the requirements of Appendix C to Ind AS 103 "Business Combination". Accordingly, the corresponding amounts for quarter ended June 30, 2024 shown in the statement, have been restated after recognising the effect of the Scheme as above.



STRIDES PHARMA SCIENCE LIMITED

CIN: L24230MH1990PLC057062

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2025**

Impact of the Scheme on the statement of standalone results

Rs. in Million

Sl. No.	Particulars	3 Months ended June 30, 2025	Preceding 3 Months ended March 31, 2025	Corresponding 3 Months ended in the previous year June 30, 2024 (Restated)	Previous year ended March 31, 2025
		UNAUDITED	AUDITED (Refer note 6)	UNAUDITED (Refer note 4)	AUDITED
I	Total Revenue	-	-	274.63	-
II	Total Expenses	-	-	295.56	-
III	Loss before tax (I- II)	-	-	(20.93)	-
IV	Tax benefit	-	-	(5.75)	-
V	Loss after tax (III - IV)	-	-	(15.18)	-
VI	Earnings per equity share (face value of Rs. 10/- each)				
	(a) Basic (Rs.)	-	-	(0.17)	-
	(b) Diluted (Rs.)	-	-	(0.17)	-

- 5 On September 25, 2023, the Board of directors of the Company approved the Scheme of Arrangement (Scheme) between Strides Pharma Science Limited, OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited (Stelis)) and Steriscience Specialties Private Limited for demerger of CDMO and Soft Gelatin Business (demerged business) of the Company. The Company received the National Company Law Tribunal (NCLT) order approving the Scheme on November 14, 2024 with appointed date of April 01, 2024. Upon filing with the Registrar of Companies "ROC", the Scheme became effective from November 27, 2024. Pursuant to the approval by NCLT, as of April 01, 2024 the demerger has been accounted for as per the Guidance in Appendix A of Ind AS 10 (Distribution of Non-cash assets to the owners). Further, the demerged business has been presented as discontinued operations as it meets the requirement of such presentation in accordance with Ind AS 105 - Non-current Assets Held for Sale and Discontinued Operations and consequently the Company has restated the financial results for quarter ended June 30, 2024.

In line with the accounting prescribed in the Scheme, the difference between the net assets transferred and the fair value of consideration amounting to Rs. 28,270.55 million has been credited to statement of profit and loss as Gain on disposal of assets attributable to discontinued operations with corresponding debit of Rs. 3,756 million and Rs. 28,271 million to the Securities Premium account and Retained earnings respectively.

**STRIDES PHARMA SCIENCE LIMITED****CIN: L24230MH1990PLC057062**

Regd. Office: Cyber One, Unit No. 902, Plot No 4 & 6, Sector 30A, Vashi, Navi Mumbai 400 703.
Corp. Office: "Strides House", Bilekahalli, Bannerghatta Road, Bangalore-560 076.

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER ENDED JUNE 30, 2025**

The comparative statement of profit and loss has been re-presented to show the discontinued operation separately from continuing operations.

Rs. in Million

Sl. No.	Particulars	3 Months ended June 30, 2025	Preceding 3 Months ended March 31, 2025	Corresponding 3 Months ended in the previous year June 30, 2024 (Restated)	Previous year ended March 31, 2025
		UNAUDITED	AUDITED (Refer note 6)	UNAUDITED (Refer note 5)	AUDITED
I	Total Revenue	-	-	-	-
II	Total Expenses	-	-	-	-
III	(Loss)/ Profit before exceptional items and tax (I - II)	-	-	-	-
IV	Exceptional Items:	-	-	-	-
V	(Loss)/ Profit before tax (III - IV)	-	-	-	-
VI	Gain on disposals (net)	-	-	28,270.55	28,270.55
VII	Tax expense/ (benefit)	-	-	-	-
VIII	Profit from discontinued operations (V + VI - VII)	-	-	28,270.55	28,270.55

6 The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures upto the end of the third quarter of the financial year, which are subjected to limited review.

7 On May 22, 2025, the Board of directors has proposed a final dividend of Rs 4 per share which shall result in cash outflow of Rs 369 millions (approx). The proposed dividend is subject to the approval of the shareholders in the Annual General Meeting.

For and on behalf of the Board

Bangalore, 29 July 2025

Badree Komandur
Managing Director and Group CEO